Mar. 22 at 4:58 PM
$ABCL
the X video posted below totally worth watching.
Jack Prescott is totally sharp and seems to know a ton about
$ABCL and has great comments on the “no BS” style of management
The random Czech guy who joins half-way through is even better.
Emir keeps focusing on concern that that real revenue is years away and as is this is a SAS business
In biotech clinical data and platform validation drives value years ahead of any approved products...once value is recognized, you raise money to fund more drug discovery and more development.
Clinical Data -> higher share price -> cheap capital -> more trials -> more clinical data….
And then, some day, billions of revenue at high margin
